| Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes DS Streetman, JS Bertino Jr, AN Nafziger Pharmacogenetics and Genomics 10 (3), 187-216, 2000 | 563 | 2000 |
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria ADM Kashuba, AN Nafziger, GL Drusano, JS Bertino Jr Antimicrobial agents and chemotherapy 43 (3), 623-629, 1999 | 492 | 1999 |
| Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs JF Rogers, AN Nafziger, JS Bertino Jr The American journal of medicine 113 (9), 746-750, 2002 | 316 | 2002 |
| Back to the future: using aminoglycosides again and how to dose them optimally GM Eliopoulos, GL Drusano, PG Ambrose, SM Bhavnani, JS Bertino, ... Clinical infectious diseases 45 (6), 753-760, 2007 | 305 | 2007 |
| Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey SJ Bowlin, BD Morrill, AN Nafziger, PL Jenkins, C Lewis, TA Pearson Journal of clinical epidemiology 46 (6), 561-571, 1993 | 291 | 1993 |
| The absolute bioavailability of oral melatonin RL DeMuro, AN Nafziger, DE Blask, AM Menhinick, JS Bertino Jr The Journal of Clinical Pharmacology 40 (7), 781-784, 2000 | 278 | 2000 |
| Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring JS Bertino Jr, LA Booker, PA Franck, PL Jenkins, KR Franck, AN Nafziger Journal of Infectious Diseases 167 (1), 173-179, 1993 | 242 | 1993 |
| Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey SJ Bowlin, BD Morrill, AN Nafziger, C Lewis, TA Pearson Journal of clinical epidemiology 49 (5), 511-517, 1996 | 226 | 1996 |
| Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs ADM Kashuba, AN Nafziger Clinical pharmacokinetics 34 (3), 203-218, 1998 | 209 | 1998 |
| A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 LS Tham, BC Goh, A Nafziger, JY Guo, LZ Wang, R Soong, SC Lee Clinical Pharmacology & Therapeutics 80 (4), 346-355, 2006 | 190 | 2006 |
| Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the … S Chainuvati, AN Nafziger, JS Leeder, A Gaedigk, GL Kearns, E Sellers, ... Clinical pharmacology & therapeutics 74 (5), 437-447, 2003 | 190 | 2003 |
| Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail” DS Streetman, JF Bleakley, JS Kim, AN Nafziger, JS Leeder, A Gaedigk, ... Clinical Pharmacology & Therapeutics 68 (4), 375-383, 2000 | 183 | 2000 |
| Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. SD Stellman, MV Djordjevic, JE Muscat, L Gong, D Bernstein, ML Citron, ... Cancer epidemiology, biomarkers & prevention: a publication of the American …, 1998 | 178 | 1998 |
| Aminoglycoside dosing weight correction factors for patients of various body sizes AM Traynor, AN Nafziger, JS Bertino Jr Antimicrobial agents and chemotherapy 39 (2), 545-548, 1995 | 144 | 1995 |
| Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients LA Keyser, M Karl, AN Nafziger, JS Bertino Archives of internal medicine 160 (10), 1485-1488, 2000 | 136 | 2000 |
| Comparison of midazolam and simvastatin as cytochrome P450 3A probes E Chung, AN Nafziger, DJ Kazierad, JS Bertino Jr Clinical pharmacology & therapeutics 79 (4), 350-361, 2006 | 130 | 2006 |
| Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults M Chen, AN Nafziger, GL Drusano, L Ma, JS Bertino Jr Antimicrobial agents and chemotherapy 50 (4), 1222-1227, 2006 | 129 | 2006 |
| Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam ADM Kashuba, JS Bertino Jr, ML Rocci Jr, RW Kulawy, DJ Beck, ... Clinical Pharmacology & Therapeutics 64 (3), 269-277, 1998 | 127 | 1998 |
| Individualized pharmacokinetic monitoring results in less aminoglycoside‐associated nephrotoxicity and fewer associated costs DS Streetman, AN Nafziger, CJ Destache, JS Bertino Jr Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (4 …, 2001 | 126 | 2001 |
| Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing DJ Demczar, AN Nafziger, JS Bertino Jr Antimicrobial agents and chemotherapy 41 (5), 1115-1119, 1997 | 126 | 1997 |
Joseph S Bertino JrBertino ConsultingVerified email at ix.netcom.com
